-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Peanut Allergy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remibrutinib in Peanut Allergy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Peanut Allergy Drug Details: LOU-064 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acalabrutinib Maleate in Peanut Allergy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acalabrutinib Maleate in Peanut Allergy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acalabrutinib Maleate in Peanut Allergy Drug Details: Acalabrutinib maleate (Calquence)...
-
Product Insights
Likelihood of Approval Analysis for Peanut Allergy
Overview How likely is it that the drugs in Peanut Allergy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Peanut Allergy Overview Peanut allergy is common, especially in children. An allergic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Allergen For Peanut Allergy in Peanut Allergy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Allergen For Peanut Allergy in Peanut Allergy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Allergen For Peanut Allergy in Peanut Allergy Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CA-002 in Peanut Allergy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CA-002 in Peanut Allergy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CA-002 in Peanut Allergy Drug Details: CA-002 is under development for the...
-
Product Insights
NewPeanut Allergy – Drugs In Development, 2024
Empower your strategies with our Peanut Allergy – Drugs In Development, 2024 report and make more profitable business decisions. Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions such as hives, redness or swelling; itching or tingling in or around the mouth and throat; digestive problems, such as diarrhea, stomach cramps, nausea or vomiting; tightening of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omalizumab in Peanut Allergy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Omalizumab in Peanut Allergy Drug Details: Omalizumab (Xolair, Bolstran) is a recombinant DNA-derived humanized IgG1-kappa...
-
Company Insights
NewDBV Technologies SA Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our DBV Technologies SA Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. DBV Technologies SA (DBV Technologies) is a biopharmaceutical company. It develops self-administered and non-invasive therapies to treat food allergies and other immunological diseases. Its product pipeline includes Viaskin peanut, Viaskin milk and Viaskin EoE indicated for the treatment of related food allergies in children. It offers clinical trial services which comprises food allergy clinical trials, milk clinical trials, egg...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tezepelumab in Eosinophilic Esophagitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tezepelumab in Eosinophilic Esophagitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tezepelumab in Eosinophilic Esophagitis Drug Details: Tezepelumab-ekko (Tezspire) is a first-in-class...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tezepelumab in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tezepelumab in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tezepelumab in Chronic Obstructive Pulmonary Disease (COPD) Drug...